Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
Circassia To Terminate AstraZeneca Deal And Transfer Assets
Details : On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 09, 2020
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
LOOKING FOR A SUPPLIER?
Reset All
